Vor Biopharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 168
- Market Cap
- $60.8M
- Introduction
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
Vor Biopharma Secures $55.6M for Cancer Therapy Trials
Vor Biopharma secured $55.6M in a private placement to fund cancer therapy trials, extending cash runway through 2025. The company focuses on engineering hematopoietic stem cells for blood cancer treatments.
Mass. Biopharma Reports Positive Data & Announces New Program
Wedbush analysts maintain Outperform rating and $11.00 price target on Vor Biopharma Inc. (VOR:NASDAQ) following positive data from VBP101 study and initial PK results for VCAR33ALLO, with strategic focus on advancing trem-cel towards a pivotal trial and expanding pipeline with new VADC45 program.
Vor Biopharma's Promising Clinical Trials and Strategic Developments Merit a Buy Rating
Justin Walsh from JonesTrading reiterated a Buy rating on Vor Biopharma (VOR) with a $18.00 price target, citing promising data from the VBP101 trial treating AML with trem-cel and MYLOTARG, and strategic discussions with the FDA around year-end 2024. Vor Biopharma also progresses with the VBP301 trial and introduces a new preclinical asset, VADC45.
© Copyright 2025. All Rights Reserved by MedPath